

I claim:

1. Film-shaped, mucoadhesive administration form having a content of at least one active agent from the group of the cannabis active agents.
2. Administration form according to claim 1, characterized in that it has a polymer matrix that serves as active substance reservoir and has mucoadhesive properties.
3. Administration form according to claim 2, characterized in that the polymer matrix contains one or more polymers which are water-soluble and/or swellable in aqueous media, said polymers preferably being selected from the group comprising starch and starch derivatives, dextran, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose or propyl cellulose, polyacrylic acid, polyacrylates, polyvinyl pyrrolidones, polyethylene oxide polymers, polyacrylamides, polyethylene glycol, gelatine, collagen, alginates, pectins, pullulan, tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar-agar, agarose, carrageenan, and natural gums, the polymer portion preferably being 5 to 95%-wt, especially preferably 15 to 75%-wt.
4. Administration form according to any one of the preceding claims, characterized in that it contains a cannabis extract or a cannabis oil, preferably in an amount of 0.5 to 50%-wt, especially preferably in an amount of 1 to 30%-wt.

5. Administration form according to any one of the preceding claims, characterized in that it contains at least one cannabinoid active agent from the group consisting of tetrahydrocannabinol, cannabinol, cannabidiol, and cannabichromen.
6. Administration form according to claim 5, characterized in that the mentioned substance(s) is/are contained in a proportion of 0.1 to 20%-wt, preferably in a proportion of 0.5 to 10%-wt.
7. Administration form according to any one of the preceding claims, characterized in that it contains tetrahydrocannabinol, preferably R-(6a,10a)-Δ-9-tetrahydrocannabinol, the active substance content preferably amounting to 0.1 to 20%-wt, especially preferably 0.5 to 10%-wt.
8. Administration form according to any one of the preceding claims, characterized in that it contains 0.5 to 20 mg, preferably 1 to 10 mg of active agent(s), preferably tetrahydrocannabinol.
9. Administration form according to any one of the preceding claims, characterized in that it contains one or more substances from the group of the flavourings, odorous substances and aromatics, especially from the group comprising menthol, eucalyptol, limonene, phenyl ethanol, camphene, pinene, seasoning aromatics such as n-butyl phthalide or cineol, as well as eucalyptus oil and thyme oil, methyl salicylate, turpentine oil, camomile oil, ethyl vanillin, 6-methyl coumarin, citronellol, and acetic acid n-butyl ester.

10. Administration form according to any one of the preceding claims, characterized in that the layer thickness thereof is 0.01 to 2 mm, preferably 0.05 to 0.5 mm.
11. Administration form according to any one of the preceding claims, characterized in that it contains one or more inactive ingredients from the group of the fillers, colourants, emulsifiers, plasticizers, sweeteners, preservatives, pH regulators, permeation-enhancing substances, and antioxidants.
12. Administration form according to any one of the preceding claims, characterized in that it has a multilayer structure, with at least one layer having an active agent content.
13. Use of an administration form according to one or more of the preceding claims for therapeutic treatment, especially for the treatment of: conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, particularly nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

14. Use according claim 14, characterized in that application is carried out to the oral mucosa, especially sublingually or buccally.